{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:20:59Z","timestamp":1793917259445,"version":"4.8.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaut.2020.102514","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T22:18:54Z","timestamp":1596579534000},"page":"102514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development"],"prefix":"10.1016","volume":"114","author":[{"given":"Arie","family":"Regev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Kiazand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie O.","family":"Omokaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian M.","family":"Di Bisceglie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert L.","family":"Bonkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Freston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack P.","family":"Uetrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonko D.","family":"Pehlivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Asif","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hewei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niti N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenal","family":"Patwardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen D.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga P.","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2020.102514_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2020.102514_bib2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.jaut.2020.102514_bib3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cpt.1123","article-title":"Clinical development and initial approval of novel immune checkpoint inhibitors in oncology: insights from a global regulatory perspective","volume":"15","author":"Serrano","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2020.102514_bib4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2020.102514_bib5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/13543784.2016.1175433","article-title":"Programming the immune checkpoint to treat hematologic malignancies","volume":"25","author":"Vick","year":"2016","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.jaut.2020.102514_bib6","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.jaut.2020.102514_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.jaut.2020.102514_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.jaut.2020.102514_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury- types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib11","series-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab","first-page":"1675","author":"Weber","year":"2013"},{"key":"10.1016\/j.jaut.2020.102514_bib12","first-page":"1","article-title":"Acute liver failure from anti-PD-1 antibody nivolumab in a patient with metastatic lung squamous cell carcinoma","volume":"1","author":"Sarmen","year":"2016","journal-title":"Austin Oncol"},{"key":"10.1016\/j.jaut.2020.102514_bib13","doi-asserted-by":"crossref","first-page":"521\u2010533","DOI":"10.1016\/j.crad.2017.04.003","article-title":"Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors","volume":"72","author":"Alessandrino","year":"2017","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.jaut.2020.102514_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jjco\/hyw167","article-title":"Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab","volume":"47","author":"Tanaka","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials. A systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaut.2020.102514_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","article-title":"Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies","volume":"15","author":"Jennings","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.jaut.2020.102514_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.jaut.2020.102514_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib21","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31","author":"Kim","year":"2013","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.jaut.2020.102514_bib24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdw649","article-title":"Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury","volume":"28","author":"Gelsomino","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.jaut.2020.102514_bib26","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2020.102514_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1610-0387.2010.07568.x","article-title":"Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma","volume":"9","author":"K\u04d3hler","year":"2011","journal-title":"JDDG"},{"key":"10.1016\/j.jaut.2020.102514_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00206","article-title":"Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1","volume":"5","author":"Kong","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2020.102514_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/intimm\/dxu095","article-title":"Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies","volume":"27","author":"Philips","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jaut.2020.102514_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40265-016-0543-x","article-title":"Pembrolizumab: a review in advanced melanoma","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2020.102514_bib31","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.jaut.2020.102514_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11901-018-0408-8","article-title":"Knowns and unknowns: the safety and efficacy of cancer immunotherapy in chronic liver disease","volume":"17","author":"Chascsa","year":"2018","journal-title":"Current Hepatology Reports"},{"key":"10.1016\/j.jaut.2020.102514_bib33","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","author":"Miller","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2020.102514_bib34","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2020.102514_bib35","series-title":"Drug-induced Livery Injury: Premarketing Clinical Evaluation","year":"2009"},{"key":"10.1016\/j.jaut.2020.102514_bib36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2020.102514_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s40264-014-0183-6","article-title":"Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials","volume":"37","author":"Avigan","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.jaut.2020.102514_bib38","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/annonc\/mdx158","article-title":"Drug-induced liver injury in oncology","volume":"28","author":"Ricart","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/liv.12988","article-title":"Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications","volume":"36","author":"Dara","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.jaut.2020.102514_bib40","series-title":"Reporting Adverse Drug Reaction. Definitions of Terms and Criteria for Their Use","article-title":"Council for international organizations of medical sciences (CIOMS). Liver and biliary system disorders (SOC 0700)","author":"Bankowski","year":"1999"},{"key":"10.1016\/j.jaut.2020.102514_bib41","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"10.1016\/j.jaut.2020.102514_bib42","doi-asserted-by":"crossref","DOI":"10.1007\/s40264-014-0182-7","article-title":"Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges","volume":"37","author":"Senior","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.jaut.2020.102514_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1033-7","article-title":"Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study","volume":"16","author":"Tweed","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.jaut.2020.102514_bib44","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease","volume":"271","author":"Watkins","year":"1994","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jaut.2020.102514_bib45","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib47","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib48","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaut.2020.102514_bib50","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib51","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib52","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib54","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib55","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.jaut.2020.102514_bib56","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib57","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trail","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2020.102514_bib58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progress after anti-CTLA-4 treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib59","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib60","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"Engl J Med"},{"key":"10.1016\/j.jaut.2020.102514_bib63","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib64","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti\u2013CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib65","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jgh.12888","article-title":"Ipilimumab-induced toxicities and the gastroenterologist","volume":"30","author":"Cheng","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2020.102514_bib66","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaut.2020.102514_bib67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib68","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMc1302338","article-title":"Hepatotoxicity with combination of vemurafenib and ipilimumab","volume":"368","author":"Ribas","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib69","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib70","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib71","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib72","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/acs.chemrestox.5b00305","article-title":"The combination of anti-CTLA-4 and PD1-\/- mice unmasks the potential of isoniazid and nevirapine to cause liver injury","volume":"28","author":"Mak","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jaut.2020.102514_bib73","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib74","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.jaut.2020.102514_bib75","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib76","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/jgh.14889","article-title":"Non-alcoholic fatty liver disease is a potential risk factor forliver injury caused by immune checkpoint inhibitor","volume":"35","author":"Sawada","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2020.102514_bib77","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-014-0033-1","article-title":"Ipilimumab administration for advanced melanoma in patients with pre-existing hepatitis B or C infection: a multicenter, retrospective case series","volume":"22","author":"Ravi","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaut.2020.102514_bib78","first-page":"403","article-title":"Immunotherapy in patients with concurrent solid organ transplant, HIV, and hepatitis B and C","volume":"28","author":"Rai","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib79","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2020.102514_bib80","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib82","series-title":"Division Director Summary Review","author":"Fda Center for Drug Evaluation and Research","year":"2014"},{"key":"10.1016\/j.jaut.2020.102514_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jaut.2020.102514_bib84","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1312772110","article-title":"Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)","volume":"110","author":"Fuller","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jaut.2020.102514_bib85","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2020.102514_bib86","first-page":"1","article-title":"PD-1 blockade in advanced melanoma in patients with Hepatitis C and\/or HIV","author":"Davar","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.jaut.2020.102514_bib87","doi-asserted-by":"crossref","first-page":"1504\u20101505","DOI":"10.1056\/NEJMp1615879","article-title":"Reevaluating eligibility criteria- balancing patient protection and participation in oncology trials","volume":"376","author":"Beaver","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib88","first-page":"3737\u20103744","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib89","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdx548","article-title":"Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient","volume":"29","author":"Biondani","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib90","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/ajg.2017.387","article-title":"Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma","volume":"112","author":"Varkaris","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2020.102514_bib91","first-page":"1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J. Immun. Canc."},{"key":"10.1016\/j.jaut.2020.102514_bib92","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"RHerbsS","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2020.102514_bib93","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib94","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib95","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib96","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib97","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib98","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma (Keynote 045)","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102514_bib99","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (keynote-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib100","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00431-011-1641-0","article-title":"Gilbert syndrome","volume":"171","author":"Fretzayas","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.jaut.2020.102514_bib102","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1399-3046.2012.01662.x","article-title":"Gilbert's syndrome-a frequent cause of unconjugated hyperbilirubinemia in children after orthotopic liver transplantation","volume":"16","author":"Kathemann","year":"2012","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.jaut.2020.102514_bib103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.jaut.2020.102514_bib104","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.29575","article-title":"Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet?","volume":"67","author":"Rammohan","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2020.102514_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105703","article-title":"Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules","volume":"9","author":"Raziorrouh","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jaut.2020.102514_bib106","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1126\/science.aal1962","article-title":"Mouse models of acute and chronic hepacivirus infection","volume":"357","author":"Billerbeck","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jaut.2020.102514_bib107","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaut.2020.102514_bib108","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib109","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann InterReck n Med"},{"key":"10.1016\/j.jaut.2020.102514_bib110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.humpath.2018.07.014","article-title":"Histologic features of autoimmune hepatitis: a critical appraisal","volume":"82","author":"Gurung","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.jaut.2020.102514_bib115","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib116","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1053\/j.gastro.2016.10.010","article-title":"Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage?","volume":"151","author":"Chalasani","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2020.102514_bib117","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/apt.15153","article-title":"Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis","volume":"49","author":"Regev","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2020.102514_bib118","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/s40264-014-0185-4","article-title":"Causality assessment for suspected DILI during clinical phases of drug development","volume":"37","author":"Regev","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.jaut.2020.102514_bib119","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.yrtph.2016.03.019","article-title":"Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort","volume":"77","author":"Shantakumar","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jaut.2020.102514_bib120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jaut.2020.102514_bib121","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2020.102514_bib122","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","article-title":"Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma","volume":"57","author":"Kleiner","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jaut.2020.102514_bib123","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jaut.2020.102514_bib124","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.gtc.2017.01.004","article-title":"Drug-induced liver injury: the hepatic pathologist's approach","volume":"46","author":"Kleiner","year":"2017","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"10.1016\/j.jaut.2020.102514_bib125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2017.05.018","article-title":"Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus antithymocyte immunoglobulins","volume":"81","author":"Spankuch","year":"2017","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.jaut.2020.102514_bib126","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib127","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib128","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Lebbe C for the PATIO group. Immune-related hepatitis with immunotherapy: are corticosteroids always needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2020.102514_bib129","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41424-018-0049-9","article-title":"Immune checkpoint inhibitor-associated colitis and hepatitis","volume":"9","author":"Reddy","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.jaut.2020.102514_bib130","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","article-title":"Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy","volume":"29","author":"Chmiel","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib131","first-page":"1","article-title":"Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy","author":"Ahmed","year":"2015","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.jaut.2020.102514_bib132","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report","volume":"67","author":"McGuire","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jaut.2020.102514_bib133","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jaut.2020.102514_bib134","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2020.102514_bib135","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following drug-induced liver injury","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120301360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120301360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:27:27Z","timestamp":1760257647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841120301360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":128,"alternative-id":["S0896841120301360"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102514","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102514"}}